Trials / Withdrawn
WithdrawnNCT04388761
Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Tambi Jarmi · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allogeneic adipose derived mesenchymal stem cells | Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
- First posted
- 2020-05-14
- Last updated
- 2023-10-18
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04388761. Inclusion in this directory is not an endorsement.